Epitope Mapping of the Variable Repetitive Region within the MB Antigen of *Ureaplasma urealyticum*

XIAOTIAN ZHENG,† KEITH LAU, MONICA FRAZIER, GAIL H. CASSELL, AND HAROLD L. WATSON*

> Department of Microbiology, University of Alabama at Birmingham Schools of Medicine and Dentistry, Birmingham, Alabama 35294

Received 3 May 1996/Returned for modification 13 June 1996/Accepted 9 August 1996

One of the major surface structures of *Ureaplasma urealyticum* recognized by antibodies of patients during infection is the MB antigen. Previously, we showed by Western blot (immunoblot) analysis that any one of the anti-MB monoclonal antibodies (MAbs) 3B1.5, 5B1.1, and 10C6.6 could block the binding of patient antibodies to MB. Subsequent DNA sequencing revealed that a unique six-amino-acid direct tandem repeat region composed the carboxy two-thirds of this antigen. In the present study, using antibody-reactive peptide scanning of this repeat region, we demonstrated that the amino acids defining the epitopes for MAbs 3B1.5, 5B1.1, and 10C6.6 are EQP, GK, and KEQPA, respectively. Peptide scanning analysis of an infected patient's serum antibody response showed that the dominant epitope was defined by the sequence PAGK. Mapping of these continuous epitopes revealed overlap between all MAb and patient polyclonal antibody binding sites, thus explaining the ability of a single MAb to apparently block all polyclonal antibody binding sites. We also show that a single amino acid difference in the sequence of the repeats of serovars 3 and 14 accounts for the lack of reactivity with serovar 14 of two of the serovar 3-specific MAbs. Finally, the data demonstrate the need to obtain the sequences of the *mba* genes of all serovars before an effective serovar-specific antibody detection method can be developed.

Ureaplasma urealyticum has been implicated in perinatal morbidity and mortality, including chorioamnionitis, premature birth, and respiratory disease in newborns (1, 2). Additional studies have also shown that U. urealyticum is the single most common microorganism isolated from the central nervous system of newborn infants (13, 14). Since disease occurs in only a subpopulation of infected individuals, it has been postulated that only some of the 14 established serovars may be responsible for causing diseases. Earlier studies suggested that a serovar-specific antibody may be required for protection against invasive diseases caused by this organism. Our preliminary studies (18) suggested that invasiveness was not likely to be limited to one or a few particular serovars and may be mediated by an adaptive property inherent in all serovars, i.e., the ability to accommodate a new environment via easily alterable surface antigens. This ability to provide a highly plastic interface between organism and host has been found in many mycoplasmas (16). The change of topography of U. urealyticum consequent to changes of its MB antigen may reflect such a property of this organism, thus providing any serovar with a possible immune system avoidance mechanism and the potential ability to alternate between a commensal and a pathogenic state. We have shown that this size-variable antigen, which presents a multiple-banding pattern on an immunoblot, is one of the major antigens recognized during infection by antibodies of patients and that antibodies against this antigen have metabolism inhibition activity in vitro (11, 15). Recently, we cloned and sequenced the mba gene of the serovar 3 reference strain and found that the associated antigen contains a region

at the carboxy end of the molecule which consists exclusively of direct tandem repeat units (17). Each repeat unit consists of six amino acids with the sequence of GKEQPA. The corresponding genetic region encompassed 62% of the gene and contained 42 1/2 repeating units. Our results showed that alteration of the repeat copy number accounted for the observed size variation. Using synthetic peptides and coupled in-vitro transcription and translation of the cloned gene, we showed that this repetitive region contained both serovar-specific and cross-reactive epitopes and was recognized by ureaplasma-infected patient antibodies.

In the present study we used antibody-reactive peptide scanning to further elucidate the immunoreactive profile of this carboxy domain (12). The commonly used approach is to produce a series of overlapping peptides covering the entire sequence of interest and determine which regions are reactive with an antibody preparation. However, with a simple sixamino-acid repeat this approach was unlikely to yield the maximum amount of information. Therefore, we chose to synthesize peptides consisting of all unique 4-mers through 18-mers (a total of three direct repeats) to more finely map the epitopes within this region. The complete list of peptides used is shown in Table 1. In all, 75 unique 4- to 18-mer pin-coupled synthetic peptides were prepared by and purchased from Chiron Mimotopes, Clayton, Australia. All peptides received N-terminal acetylation and were covalently bound to pins via their C termini. Reactivities of the peptides with three monoclonal antibodies (MAbs), with serum from one U. urealyticum-infected patient, with pooled antisera from three rabbits hyperimmunized with serovar 3, and with the same rabbit anti-serovar 3 sera absorbed with whole serovar 3 organisms (to remove antiserovar 3 antibodies) were determined by enzyme-linked immunosorbent assay with peroxidase conjugates as described in the instructions from the manufacturer. Rabbit antisera were prepared as previously described (15). For preparation of absorbed rabbit antisera, whole serovar 3 organisms were sus-

^{*} Corresponding author. Mailing address: Department of Microbiology, BBRB 618, University of Alabama at Birmingham, Birmingham, AL 35294. Phone: (205) 934-9188. Fax: (205) 975-5965. Electronic mail address: harold_watson@micro.microbio.uab.edu.

[†] Present address: Division of Clinical Microbiology, Hilton 470, Mayo Clinic, Rochester, MN 55905.

TADLE 1 Could de la della f	· · · · · · · · · · · · · · · · · · ·		1	
IABLE I Synthetic pentides t	om the <i>U ureavacum</i> serovar	5 MIB antigen carnovy reneat	antibod	vreactivity
TIDEE 1. Synthetic peptides in	on the o. <i>weavyweant</i> serovar	s wild antigen earboxy repeat	aomani testea foi antiooa	y reactivity

1 GKEQ 39 EOPAGKEQPA 2 KEOP 40 OPAGKEQPAG 3 EOPA 41 PAGKEOPAG 4 OPAG 42 AGKEOPAGK 4 OPAG 42 AGKEOPAGK 6 AGKE 43 GKEOPAGK 7 GKEOP 45 EOPAGKEOPAG 9 EOPAG 47 PAGKEOPAGK 9 EOPAG 47 PAGKEOPAGK 10 OPAGK 48 AGKEOPAGKEO 11 PAGKE 49 GKEOPAGKEO 12 AGKEO 50 KEOPAGKEOPAGK 13 GKEOPAGK 51 EOPAGKEOPAGK 14 KEOPAGK 52 OPAGKEOPAGKEO 15 EOPAGK 53 PAGKEOPAGKEOPAG 16 OPAGKE 54 AGKEOPAGKEOPAGK 17 PAGKEO 55 KEOPAGKEOPAGK 18 AGKEOPA 58 OPAGKEOPAGKE 20 EOPAGKEO	Peptide ^a	Sequence	Peptide	Sequence
2 KEOP 40 OPAGKEOPAG 3 EOPA 41 PAGKEOPAGK 4 OPAG 41 PAGKEOPAGK 5 PAGK* 42 AGKEOPAGKE 6 AGKE 43 GKEOPAGKEOPA 7 GKEOPA 45 EOPAGKEOPAGK 8 KEOPA 46 OPAGKEOPAGKE 9 EOPAG 47 PAGKEOPAGKE 10 OPAGKE 48 AGKEOPAGKE 11 PAGKEO 50 KEOPAGKEOPA 12 AGKEO 50 KEOPAGKE 13 GKEOPA' 51 EOPAGKEOPAGKE 14 KEOPAGK 53 PAGKEOPAGKEOP 15 EOPAGKEO 55 GKEOPAGK 19 GKEOPAG 55 GKEOPAGKEOP 20 KEOPAGKE 58 OPAGKEOPAGKEOP 21 EOPAGKE 58 OPAGKEOPAGKEOP 22 OPAGKEOPAGK 53 EOPAGKEOPAGKEOP 23	1	GKEQ	39	FOPAGKEOPA
3 EQPA 41 PAGKEQPAGK 4 QPAG 41 PAGKEQPAGK 4 QPAG 42 AGKEQPAGKE 6 AGKE 44 KEQPAGKEOP 6 AGKE 44 KEQPAGKEOPAG 8 KEOPA 46 OPAGKEOPAGG 9 EQPAG 47 PAGKEOPAGKE 10 OPAGK 48 AGKEOPAGKE 11 PAGKE 49 GKEOPAGKEOPAG 12 AGKEQ 50 KEOPAGKEOPAG 13 GKEOPAG 51 EOPAGKEOPAGKE 14 KEOPAGK 53 PAGKEOPAGKEO 15 EOPAGKE 54 AGGKEOPAGKEO 16 OPAGKE 55 GKEOPAGKEOPAG 19 GKEOPAG 57 EOPAGKEOPAGKEO 20 KEOPAGKE 58 OPAGKEOPAGK	2	KEQP	40	OPAGKEOPAG
4 OPAG 42 AGKEOPAGKE 5 PAGK* 43 GKEOPAGKEOP 6 AGKE 43 GKEOPAGKEOP 7 GKEOPA 45 EOPAGKEOPAG 8 KEOPAA 46 OPAGKCEOPAGK 9 EOPAG 47 PAGKEOPAGKE 10 OPAGK 47 PAGKEOPAGKEOPA 11 PAGKE 49 GKEOPAGKEOPA 12 AGKEO 50 KEOPAGKEOPAGK 13 GKEOPA* 51 EOPAGKEOPAGK 14 KEOPAGK 52 OPAGKEOPAGKE 15 EOPAGK 53 PAGKEOPAGKEOP 16 OPAGKE 54 AGKEOPAGKEOP 17 PAGKEOP 56 KEOPAGKEOPAGK 18 AGKEOPAGK 57 EOPAGKEOPAGKE 20 KEOPAGKE 58 OPAGKEOPAGKEOP 21 EOPAGKE 58 OPAGKEOPAGKEOP 22 OPAGKEOPAGKE 59 PAGKEOPAGKEOP 23 PAGKEOP 61 GKEOPAGKEOP 24 <	3	EQPA	41	PAGKEOPAGK
5 PAGK ^b 43 GKEOPAGKEOP 6 AGKE 44 KEOPAGKEOPA 7 GKEOP 45 EOPAGKEOPAG 8 KEOPA 46 OPAGKEOPAGKE 9 EOPAGG 47 PAGKEOPAGKE 10 OPAGK 48 AGKEOPAGKE 11 PAGKE 49 GKEOPAGKEOPAG 12 AGKEO 50 KEOPAGKEOPAG 13 GKEOPAG 51 EOPAGKEOPAGKE 14 KEOPAG 52 OPAGKEOPAGKEO 15 EOPAGK 53 PAGKEOPAGKEO 16 OPAGKEO 55 GKEOPAGKEO 17 PAGKEO 55 GKEOPAGKEO 18 AGKEOP 55 GKEOPAGKEO 19 GKEOPAGK 58 OPAGKEOPAGKEO 20 KEOPAGK 58 OPAGKEOPAGKEO 21 EOPAGKEO 59 PAGKEOPAGKEOPAGKEO 22 OPAGKEO 60 AGKEOPAGKEOPAGKEOPAGKEOPAGKEOPAGKEOPAGKEOP	4	QPAG	42	AGKEOPAGKE
6 AGKE 44 KEQPAGKEQPA 7 GKEQP 45 EQPAGKEQPAG 8 KEQPA 46 OPAGKEQPAGK 9 EQPAG 47 PAGKEQPAGKE 10 OPAGK 48 AGKEQPAGKE 11 PAGKEQ 49 GKEQPAGKEQPA 12 AGKEQ 49 GKEQPAGKEQPAG 13 GKEQPA' 51 EOPAGKEQPAGKE 14 KEQPAG 52 OPAGKEQPAGKE 15 EOPAGK 53 PAGKEQPAGKEQ 16 OPAGKEQ 54 AGKEQPAGKEQPAG 17 PAGKEQP 56 GKEQPAGKEQPAG 18 AGKEQP 56 GKEQPAGKE 19 GKEQPAG 57 EOPAGKEQPAGKE 20 KEQPAGK 58 OPAGKEQPAGKEQ 21 EQPAGKE 59 PAGKEQPAGKEQP 22 OPAGKEQP 61 GKEQPAGKEQP 23 PAGKEQP 61 GKEQPAGKEQP 24 AGKEQPA 62 EQPAGKEQPA 25 GKEQPAGK 63 EOPAGKEQPAGKEQP 26 KEQPAGKE 64 OPAGKEQPAGKEQP 27 EOPAGKEQP 65 FAGKEQPAGKEQP	5	PAGK ^b	43	GKEOPAGKEOP
7 GKEOP 45 EOPAGKEOPAG 8 KEOPA 46 OPAGKEOPAGK 9 EOPAG 47 PAGKEOPAGKE 10 OPAGK 48 AGKEOPAGKE 11 PAGKE 48 AGKEOPAGKEO 11 PAGKE 49 GKEOPAGKEOPA 12 AGKEO 50 KEOPAGKEOPAGK 13 GKEOPAG 51 EOPAGKEOPAGKE 14 KEOPAGK 53 PAGKEOPAGKEO 15 EOPAGK 53 PAGKEOPAGKEOPAGKEOPAGKEOPAGKEOPAGKEOPAGKEOPAGKEOPAGKEOPAGKEOPAGKEOPAGKEOP 16 OPAGKEO 55 GKEOPAGKEOPAGKEOPAGKEOPAGKEOPAGKEOPAGKEOP 17 PAGKEOPAGK 53 PAGKEOPAGKEOPAGKEOPAGKEOPAGKEOPAGKEOPAGKEO 20 CKEOPAGKEO 56 KEOPAGKEOPAGKEOPAGKEO 21 EOPAGKEOP 60 AGKEOPAGKEOPAGKEO 22 OPAGKEOP 61 GKEOPAGKEOPAGKEO 24 AGKEOPAGK 63 EOPAGKEOPAGKEO 25 GKEOPAGKEO 64 OP	6	AGKE	40	KEOPAGKEOPA
8 KEQPA 46 OPAGKEQPAGK 9 EQPAG 47 PAGKEQPAGK 9 OPAGK 48 AGKEQPAGKE 11 PAGKE 48 AGKEQPAGKEQPAG 12 AGKEQ 50 KEQPAGKEQPAG 13 GKEQPAG 51 EQPAGKEQPAGKE 14 KEQPAGK 52 QPAGKEQPAGKE 15 EQPAGK 53 PAGKEQPAGKEQ 16 QPAGKE 54 AGKEQPAGKEQPAG 18 AGKEQPA 55 GKEQPAGKEQPAGKE 19 GKEQPAGK 58 QPAGKEQPAGKEQ 20 KEQPAGKEQP 56 KEQPAGKEQPAGKEQ 21 EQPAGKE 59 PAGKEQPAGKEQP 22 QPAGKEQPA 60 AGKEQPAGKEQPA 23 PAGKEQPA 62 KEQPAGKEQPAGKE 24 AGKEQPA 62 KEQPAGKEQPAGKE 25 GKEQPAGKE 64 OPAGKEQPAGKEQPA 26 KEQPAGKEQPA 65 PAGKEQ	7	GKEQP	45	FOPAGKEOPAG
9 EOPAG 47 PAGKEQPAGKE 10 OPAGK 48 AGKEQPAGKEQ 11 PAGKE 49 GKEOPAGKEQPA 12 AGKEQ 50 KEOPAGKEQPAGK 13 GKEOPAG 51 EOPAGKEQPAGK 14 KEOPAGK 51 EOPAGKEQPAGK 15 EOPAGKE 54 AGKEOPAGKEQP 16 OPAGKEQP 55 GKEOPAGKEQPAGK 19 GKEOPAGK 57 EOPAGKEQPAGKE 20 KEOPAGK 58 OPAGKEQPAGKEQ 21 EOPAGK 58 OPAGKEQPAGKEQ 22 OPAGKEQPAGK 57 EOPAGKEQPAGKEQ 21 EOPAGKE 59 PAGKEQPAGKEQPA 23 PAGKEQPA 60 AGKEQPAGKEQPA 24 AGKEOPAGKE 64 OPAGKEQPAGKEQPA 25 GKEQPAGKE 64 OPAGKEQPAGKEQPA 26 KEOPAGKEQP 66 GKEOPAGKEQPA 27 EOPAGKEQPA 67 <	8	KEQPA	46	OPAGKEOPAGK
10 OPAGK 48 AGREOPAGKEQ 11 PAGKE 49 GKEOPAGKEQ 12 AGKEQ 50 KEOPAGKEQPAG 13 GKEOPAG 50 KEOPAGKEQPAGKE 14 KEOPAGKE 51 EPAGKEQPAGKE 15 EOPAGK 53 PAGKEQPAGKEO 16 OPAGKE 54 AGKEQPAGKE 17 PAGKEQPAGK 55 GKEQPAGKEOPAGK 18 AGKEQP 56 KEOPAGKEQPAGK 19 GKEQPAGK 58 OPAGKEQPAGKE 20 KEQPAGKE 59 PAGKEQPAGKEQP 21 EOPAGKE 59 PAGKEQPAGKEQPAGK 23 PAGKEQPA 61 GKEQPAGKEQPAGKE 24 AGKEQPA 62 KEOPAGKEQPAGKEQPA 25 GKEQPAGK 63 EQPAGKEQPAGKEQPA 26 KEOPAGKEQPA 62 PAGKEQPAGKEQPA 27 EQPAGKEQPA 62 KEOPAGKEQPA 28 OPAGKEQPA 62	9	EQPAG	40	PAGKEOPAGKE
11 PAGKE 49 GKEQPAGKEOPA 12 AGKEQ 50 KEOPAGKEOPAG 13 GKEQPAC 51 EQPAGKEOPAGK 14 KEOPAGK 52 OPAGKEOPAGKE 15 EQPAGK 53 PAGKEQPAGKEO 16 OPAGKE 54 AGKEOPAGKEOPAGK 17 PAGKEQ 55 GKEQPAGKEOPAGK 18 AGKEOPAG 57 EQPAGKEOPAGKEO 19 GKEQPAGK 58 OPAGKEOPAGKEOP 20 KEQPAGK 58 OPAGKEOPAGKEOP 21 EQPAGKE 59 PAGKEOPAGKEOP 22 OPAGKEOP 61 GKEOPAGKEOPAGK 23 PAGKEOPA 62 KEOPAGKEOPAGKE 24 AGKEOPA 62 KEOPAGKEOPAGKE 25 GKEQPAGK 63 EOPAGKEOPAGKEOP 26 KEOPAGKEO 64 OPAGKEOPAGKEOPAGKE 27 EQPAGKEOP 65 PAGKEOPAGKEOPA 28 OPAGKEOPA 67 KEOPAAGKEOPA 29 PAGKEOPA 67 KEOPAAGKEOPA </td <td>10</td> <td> QPAGK</td> <td>48</td> <td>AGKEOPAGKEO</td>	10	QPAGK	48	AGKEOPAGKEO
12 AGKEQ 50 KEQPAGKEOPAG 13 GKEQPAG 51 EOPAGKEOPAGK 14 KEQPAGK 52 OPAGKEOPAGKE 15 EOPAGK 53 PAGKEOPAGKEOP 16 OPAGKEO 54 AGKEOPAGKE 17 PAGKEO 55 GKEOPAGKE 18 AGKEOPAGK 55 GKEOPAGKE 19 GKEOPAGK 56 KEOPAGKEOPAGKE 20 KEOPAGKE 59 PAGKEOPAGKEOP 21 EOPAGKEO 59 PAGKEOPAGKEOPAGKE 23 PAGKEOPAGK 63 EOPAGKEOPAGKEOPAGKE 24 AGKEOPAGK 63 EOPAGKEOPAGKE 25 GKEOPAGK 63 EOPAGKEOPAGKE 26 KEOPAGKE 64 OPAGKEOPAGKE 27 EOPAGKEOP 66 GKEOPAGKEOPA 28 OPAGKEOPA 67 KEOPAGKEOPA 29 PAGKEOPA 67 KEOPAGKEOPA 30 AGKEOPAGKE 68 EOPAGKEOPAGKEOPA 31 GKEOPAGKEO 68 EOPAGKEOPAGKEOPA<	11	PAGKE	40	GKEOPAGKEOPA
13 GKEOPA ^c 51 EQPAGKEOPAGK 14 KEOPAG 52 OPAGKEOPAGKE 15 EOPAGK 53 PAGKEOPAGKE 16 OPAGKE 54 AGKEOPAGKEOPAGKE 17 PAGKEOP 56 GKEOPAGKE 19 GKEOPAG 57 EOPAGKEOPAGKE 20 KEOPAGK 58 OPAGKEOPAGKE 21 EOPAGKE 59 PAGKEOPAGKEOPAGKE 22 OPAGKEOPA 61 GKEOPAGKEOPAGKE 23 PAGKEOPA 62 KEOPAGKEOPAGKE 24 AGKEOPAGK 63 EQPAGKEOPAGKE 25 GKEOPAGK 63 EQPAGKEOPAGKE 26 KEOPAGKE 64 OPAGKEOPAGKEQ 27 EOPAGKE 64 OPAGKEOPAGKEQ 28 OPAGKEOPA 65 PAGKEOPAGKEQP 29 PAGKEOPA 66 GKEOPAGKEQP 30 AGKEOPAG 67 EOPAGKEOPAGKEQP 31 GKEOPAGKE 69 OPAGKEOPAGKEQP 32 KEOPAGKEQP 66 EOPAGKEOPAGKE	12	AGKEQ	50	KEOPAGKEOPAG
14 KEQPAG 52 OPAGKEQPAGKE 15 EQPAGK 53 PAGKEQPAGKEQP 16 OPAGKE 54 AGKEQPAGKEQP 17 PAGKEQP 55 GKEQPAGKEQPAG 18 AGKEQP 56 KEQPAGKEQPAGK 19 GKEQPAGK 58 OPAGKEQPAGKEQ 20 KEQPAGK 58 OPAGKEQPAGKEQP 21 EQPAGKE 59 PAGKEQPAGKEQP 22 OPAGKEQP 60 AGKEQPAGKEQP 23 PAGKEQP 61 GKEQPAGKEQPAGKEQP 24 AGKEQPAGK 62 EOPAGKEQPAGKEQ 25 GKEQPAGKEQ 62 EOPAGKEQPAGKEQP 26 KEQPAGKEQ 64 OPAGKEQPAGKEQP 27 EOPAGKEQ 65 PAGKEQPAGKEQP 28 OPAGKEQPAG 66 GKEQPAGKEQPA 29 PAGKEQPAG 67 KEQPAGKEQPA 31 GKEQPAGKE 69 OPAGKEQPAGKEQPA 32 KEQPAGKEQ 70 GKEQPAGKEQPA 33 EQPAGKEQPA 72 EOPAGKEQ	13	GKEQPA ^c	51	FOPAGKEOPAGK
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	14	KEQPAG	52	OPAGKEOPAGKE
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	15	EQPAGK	53	PAGKEOPAGKEO
17PAGKEQ18AGKEQP18AGKEQPAG19GKEQPAGK20EQPAGK21EQPAGKE22OPAGKEQ23PAGKEQPA24AGKEQPAGK25GKEQPAGK26KEOPAGK27EQPAGKE28OPAGKEQP29AGKEQPAGKE29PAGKEQPAGKE20GKEQPAGKE21EOPAGKE22OPAGKEQP23PAGKEQPA24GKEOPAGKE25GKEOPAGKE26KEOPAGKE27EOPAGKE28OPAGKEQPA29PAGKEOPA29PAGKEOPA20GKEOPAGKE20AGKEOPA21GKEOPAGKE22OPAGKEQPA23GKEOPAGKE24GKEOPAGKE25GKEOPAGKE26KEOPAGKEQ27EOPAGKEQ28OPAGKEOPA29AGKEOPA30AGKEOPA31GKEOPAGKE32EOPAGKEQ33EOPAGKEQ34OPAGKEOPA35PAGKEOPAG36AGKEOPAGK37GKEOPAGKE38KEOPAGKEOP38KEOPAGKEOP38KEOPAGKEOP38KEOPAGKEOP38KEOPAGKEOP38KEOPAGKEOP	16	QPAGKE	53	AGKEOPAGKEOP
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	17	PAGKEQ	55	GKEOPAGKEOPAG
19GKEQPAG50REQPAGKEQPAGKE20KEQPAGK57EQPAGKEQPAGKE21EQPAGKE58QPAGKEQPAGKEQP22QPAGKEQ60AGKEQPAGKEQPA23PAGKEQPA61GKEQPAGKEQPAGKE24AGKEQPA61GKEQPAGKEQPAGKE25GKEQPAGK63EQPAGKEQPAGKEQ26KEQPAGKEQ64QPAGKEQPAGKEQP27EQPAGKEQP65PAGKEQPAGKEQP28QPAGKEQPA66GKEQPAGKEQPA29PAGKEQPAG67GKEQPAGKEQPAGKEQ30AGKEQPAGKE68EQPAGKEQPAGKEQP31GKEQPAGKEQ68EQPAGKEQPAGKEQP33EQPAGKEQ70GKEQPAGKEQPAGKEQP34QPAGKEQPA72EQPAGKEQPAGKEQP35PAGKEQPAG73GKEQPAGKEQPAGKEQPA36AGKEQPAGK74KEQPAGKEQPAGKEQPA38KEQPAGKEQ75GKEQPAGKEQPAGKEQPA	18	AGKEQP	55	KEOPACKEOPACK
20KEQPAGK57Der AGREQPAGKEQ21EQPAGKE59PAGKEQPAGKEQP22QPAGKEQ60AGKEQPAGKEQPA23PAGKEQPA61GKEQPAGKEQPAGKE24AGKEQPAGK62KEQPAGKEQPAGKE25GKEQPAGKE64QPAGKEQPAGKEQPA26KEQPAGKEQP65PAGKEQPAGKEQPA27EQPAGKEQP66GKEQPAGKEQPA28QPAGKEQPA65PAGKEQPAGKE29PAGKEQPA66GKEQPAGKEQPA30AGKEQPAGKE66GKEQPAGKEQPA31GKEQPAGKEQ68EQPAGKEQPA32KEQPAGKEQ70GKEQPAGKEQPA33EQPAGKEQP71KEQPAGKEQPA34QPAGKEQPA72EQPAGKEQPAGKEQPA35PAGKEQPAG73GKEQPAGKEQPA36AGKEQPAGKEQ73GKEQPAGKEQPAGKEQPA36AGKEQPAGKEQ74KEQPAGKEQPAGKEQPA38KEOPAGKEQ75GKEQPAGKEQPAGKEQPA	19	GKEQPAG	57	EOPACKEOPACKE
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	20	KEQPAGK	58	OPAGKEOPAGKEO
22QPAGKEQ39TAGKEQPAGKEQPA23PAGKEQP60AGKEQPAGKEQPA24AGKEQPA61GKEQPAGKE25GKEQPAGK62KEQPAGKEQPA26KEQPAGKEQ64QPAGKEQPAGKEQPA27EQPAGKEQP65PAGKEQPAGKEQPA28QPAGKEQP65PAGKEQPAGKEQPA29PAGKEQPAG66GKEQPAGKEQPAGKEQPA30AGKEQPAG66GKEQPAGKEQPA31GKEQPAGKE69QPAGKEQPAGKEQPA32KEQPAGKEQ70GKEQPAGKEQPA33EQPAGKEQP71KEQPAGKEQPAGKEQPA34QPAGKEQPAG72EQPAGKEQPAGKEQPA35PAGKEQPAG73GKEQPAGKEQPA36AGKEQPAGKEQ74KEQPAGKEQPAGKEQPA37GKEQPAGKEQP75GKEQPAGKEQPAGKEQPA38KEOPAGKEQP75GKEQPAGKEQPAGKEQPA	21	EQPAGKE	50	PAGKEOPAGKEOP
23PAGKEQP00AGKEQPAGKE24AGKEQPA61GKEQPAGKE25GKEQPAGK62KEQPAGKEQPAGKE26KEQPAGKEQ63EQPAGKEQPAGKEQP27EQPAGKEQP65PAGKEQPAGKE	22	OPAGKEO	60	
24AGKEQPA01OKEQFAOKBQFAOKE25GKEQPAGK62KEQPAGKEQPAGKE26KEQPAGKE63EQPAGKEQPAGKEQ27EQPAGKEQP64QPAGKEQPAGKEQPA28QPAGKEQPA65PAGKEQPAGKEQPA29PAGKEQPAG65GKEQPAGKEQ30AGKEQPAG67KEQPAGKEQPAGKEQ31GKEQPAGKE68EQPAGKEQPAGKEQPA32KEQPAGKEQ69QPAGKEQPAGKEQPA33EQPAGKEQP70GKEQPAGKEQPA34QPAGKEQPAG71KEQPAGKEQPAGKEQP35PAGKEQPAG72EQPAGKEQPAGKEQPA36AGKEQPAGK73GKEQPAGKEQPAGKEQPA37GKEQPAGKEQ74KEQPAGKEQPAGKEQPA38KEOPAGKEQP75GKEQPAGKEQPAGKEQPA	23	PAGKEOP	61	
25GKEQPAGK62KEQPAGKEQ26KEQPAGKE63EQPAGKEQPAGKEQ27EQPAGKEQ64OPAGKEQPAGKEQPA28QPAGKEQP65PAGKEQPAGKEQPA29PAGKEQPAG66GKEQPAGKEQPAGKEQ30AGKEQPAG67KEQPAGKEQPAGKEQ31GKEQPAGKE68EQPAGKEQPAGKEQPA32KEQPAGKEQ69QPAGKEQPAGKEQPA33EQPAGKEQP70GKEQPAGKEQPA34QPAGKEQPAG71KEQPAGKEQPAGKEQPA35PAGKEQPAG72EQPAGKEQPAGKEQPA36AGKEQPAGKEQ73GKEQPAGKEQPAGKEQPA37GKEQPAGKEQPAG74KEQPAGKEQPAGKEQPA38KEOPAGKEQP75GKEQPAGKEQPAGKEQPA	24	AGKEOPA	62	
26KEQPAGKE00EQTAGKEQPAGKEQP27EQPAGKEQ64QPAGKEQPAGKEQPA28QPAGKEQP65PAGKEQPAGKEQPA29PAGKEQPAG66GKEQPAGKEQPAGKEQ30AGKEQPAG67KEQPAGKEQPAGKEQ31GKEQPAGKE68EQPAGKEQPAGKEQPA32KEQPAGKEQ69QPAGKEQPAGKEQPA33EQPAGKEQP70GKEQPAGKEQPAGKEQP34QPAGKEQPAG71KEQPAGKEQPAGKEQP35PAGKEQPAG73GKEQPAGKEQPAGKEQPA36AGKEQPAGK73GKEQPAGKEQPAGKEQPA37GKEQPAGKEQ74KEQPAGKEQPAGKEQPA38KEQPAGKEQP75GKEQPAGKEQPAGKEQPA	25	GKEOPAGK	62	
27EQPAGKEQ04OFAGKEQPAGKEQPA28QPAGKEQP65PAGKEQPAGKEQPA29PAGKEQPAG66GKEQPAGKEQPAGKEQ30AGKEQPAG67KEQPAGKEQPAGKEQ31GKEQPAGKE68EQPAGKEQPAGKEQPA32KEQPAGKEQ69QPAGKEQPAGKEQPA33EQPAGKEQP70GKEQPAGKEQPAGKEQP34QPAGKEQPAG71KEQPAGKEQPAGKEQP35PAGKEQPAGK73GKEQPAGKEQPAGKEQPA36AGKEQPAGK73GKEQPAGKEQPAGKEQPA37GKEQPAGKEQ74KEQPAGKEQPAGKEQPA38KEQPAGKEQP75GKEQPAGKEQPAGKEQPA	26	KEOPAGKE	64	
28QPAGKEQP03FAGKEQPAGKEQPA29PAGKEQPAG66GKEQPAGKEQPAGKEQ30AGKEQPAG66EQPAGKEQPAGKEQ31GKEQPAGKE68EQPAGKEQPAGKEQP32KEQPAGKEQ69OPAGKEQPAGKEQPA33EQPAGKEQP70GKEQPAGKEQPAGKEQP34QPAGKEQPAG71KEQPAGKEQPAGKEQP35PAGKEQPAGK73GKEQPAGKEQPAGKEQPA36AGKEQPAGK73GKEQPAGKEQPAGKEQPA37GKEQPAGKEQ74KEQPAGKEQPAGKEQPA38KEQPAGKEQP75GKEQPAGKEQPAGKEQPA	27	EOPAGKEO	65	
29PAGKEQPA00OREQPAGKEQPAGKEQ30AGKEQPAG67KEQPAGKEQPAGKEQ31GKEQPAGKE68EQPAGKEQPAGKEQPA32KEQPAGKEQ69QPAGKEQPAGKEQPA33EQPAGKEQP70GKEQPAGKEQPAGKEQP34QPAGKEQPAG71KEQPAGKEQPAGKEQP35PAGKEQPAGK72EQPAGKEQPAGKEQPA36AGKEQPAGK73GKEQPAGKEQPAGKEQP36AGKEQPAGK74KEQPAGKEQPAGKEQPA38KEQPAGKEQP75GKEQPAGKEQPAGKEQPA	28	OPAGKEOP	66	
30AGKEQPAG67KEQPAGKEQP31GKEQPAGKE68EQPAGKEQPAGKEQP32KEQPAGKEQ68OPAGKEQPAGKEQPA33EQPAGKEQP70GKEQPAGKEQPAGKEQP34QPAGKEQPAG71KEQPAGKEQPAGKEQP35PAGKEQPAG72EQPAGKEQPAGKEQPA36AGKEQPAGK73GKEQPAGKEQPAGKEQP36AGKEQPAGKEQ74KEQPAGKEQPAGKEQPA38KEOPAGKEQP75GKEQPAGKEQPAGKEQPA	29	PAGKEOPA	67	
31GKEQPAGKE08EQPAGKEQPAGKEQPAGKEQPAGKEQPAGKEQPAGKEQPAGKEQPAGKEQPAGKEQP32KEQPAGKEQ69QPAGKEQPA	30	AGKEOPAG	69	
32KEQPAGKEQ69OFAGKEQPAGKEQPAGKEQPAGKEQ33EQPAGKEQP70GKEQPAGKEQPAGKEQ34QPAGKEQPA71KEQPAGKEQPAGKEQP35PAGKEQPAG72EQPAGKEQPAGKEQPA36AGKEQPAGK73GKEQPAGKEQPAGKEQPAGKEQPA36GKEQPAGKEQ74KEQPAGKEQPAGKEQPA37GKEQPAGKEQP75GKEQPAGKEQPAGKEQPA	31	GKEOPAGKE	60	
33EQPAGKEQP70OKEQPAGKEQPAGKEQP34QPAGKEQPA71KEQPAGKEQPAGKEQP35PAGKEQPAG72EQPAGKEQPAGKEQPA36AGKEQPAGK73GKEQPAGKEQPAGKEQP37GKEQPAGKEQP74KEQPAGKEQPAGKEQPA38KEQPAGKEQP75GKEQPAGKEQPAGKEQPA	32	KEOPAGKEO	70	
34	33	EOPAGKEOP	70	
35 PAGKEQPAG 72 EQFAGKEQFAGKEQFA 36 AGKEQPAGK 73 GKEQPAGKEQPAGKEQPA 37 GKEQPAGKEQP 74 KEQPAGKEQPAGKEQPA 38 KEQPAGKEQP 75 GKEQPAGKEQPAGKEQPA	34	OPAGKEOPA	71	
36	35	PAGKEOPAG	72	
37 GKEQPAGKEQ /4 KEQPAGKEQPAGKEQPA 38 KEQPAGKEQP 75 GKEQPAGKEQPAGKEQPA	36	AGKEOPAGK	/3	
38 KEOPAGKEOP /3 GKEOPAGKEOPAGKEOPAGKEOPA	37	GKEOPAGKEO	/4 75	KEQPAGKEQPAGKEQPA
	38	KEOPAGKEOP	/>	GKEQPAGKEQPAGKEQPAGKEQPA

^{*a*} Peptide numbers are as in Fig. 1.

^b Major epitope reactive with patient serum.

^c GKEQPA is one complete repeat unit.

pended in a 1:10 dilution of rabbit anti-serovar 3 serum at a concentration of 1 mg of organism protein per ml of diluted serum. The suspension was kept at 4°C overnight with rocking. The absorbed samples were centrifuged at $10,000 \times g$ for 25 min at 4°C. The supernatant (absorbed serum) was removed and stored at -20° C until use.

The three MAbs and patient serum tested had been characterized previously by immunoblotting (15). Among the MAbs, 3B1.5 reacts strongly with serovar 3 and reacts weakly with other serovars, 5B1.1 recognizes serovars 3 and 14, and 10C6.6 is serovar 3 specific. All of these MAbs were found to react with a synthetic peptide composed of three repeats in our previous study (17). As determined by immunoblotting, the patient serum (patient B2) showed a strong cross-reaction between serovars 3 and 14 (also a less intense reaction with serovar 1), similar to that seen for MAb 5B1.1. Like the patient serum, the rabbit anti-serovar 3 sera also showed strong crossreactivity between serovars 3 and 14 (data not shown).

The results of the antibody reactivity testing of the pincoupled peptides are shown in Fig. 1. Separate experiments were performed for each antibody tested. A comparison of Fig. 1a and Table 1 (i.e., identification of the longest common sequence in all peptides reactive with a single MAb) indicated that specific amino acid sequences were required for the epitopes for each MAb, as follows: MAb 5B1.1 required GK, MAb 3B1.5 required EQP, and MAb 10C6.6 required KEQPA. It appears unusual for an epitope defined solely by GK, such as that required by MAb 5B1.1, to display the degree of specificity seen for this MAb (15). The MAb had been previously shown to react only with serovars 3 and 14 and not to react with other mycoplasmas, which implies that GK is a rare amino acid combination, although this is unlikely. Therefore, verification of the epitopes for 5B1.1 and 3B1.5 will necessitate the evaluation of unique di- and tripeptides. We anticipate that these twoand three-residue sequences will be found to be critical but not sufficient for the formation of the complete epitopes; conformational or charge properties of neighboring residues will contribute to the total definition of these epitopes. The schematic diagram of the serovar 3 sequence (Fig. 2) indicates that all epitopes detected are present in only two direct repeats and that, as previously demonstrated, binding of any one MAb should result in blocking of the other MAbs.

As seen in Table 1 and Fig. 1a, the major patient antibodyreactive epitope, PAGK, does not correspond to that of any of the MAbs. However, PAGK does overlap epitopes defined by



FIG. 1. Peptide scan of anti-*U. urealyticum* serovar 3 antibodies. Pin-bound peptides listed in Table 1 were reacted with antibodies according to the manufacturer's instructions. (a) Reactions with MAbs and patient serum. MAb ascites fluid was diluted 1:2,000 and patient serum was diluted 1:800 before reaction with the pin-bound peptides. The patient serum responses (A_{405} , measured as optical density [O.D.]) to each individual peptide (1 to 75) are shown. The peptides reactive with each MAb are indicated by the bars below the patient scan. For this preliminary scan, only the easily detected peak responses (>0.25 nm) are defined for the patient serum. These patient responses are outlined in Table 1 and include responses to peptides 5, 10, 20, 25, 36, 41, 46, 51, 56, and 61. The peptides reactive with MAb 5B1.1 were peptides 1, 5, 6, 7, and 10 to 75 (corresponding to GK); those reactive with MAb 3B1.5 were peptides 2, 3, 7, 8, 9, 13, 14, 15, and 18 to 75 (corresponding to EQP); and those reactive with MAb 5B1.1, and peptide 22, which contains no GK, was positive with MAb 5B1.1, and peptide 22, which contains no EQP, was positive with MAb 3B1.5. These positive results were most likely due to nonspecific antibody interaction with the pins, and with a total of 75 reactions per MAb, these discrepancies do not alter the data interpretation. (b) Individual pin reactions of MAb 10C6.6 (black bars), rabbit anti-serovar 3 antisera (shaded bars), and rabbit anti-serovar 3 antisera absorbed with serovar 3 whole cells (open diamonds).

the three MAbs; therefore, any one of the MAbs could block this patient response as previously demonstrated (15).

Figure 1b shows the individual pin reactions of the rabbit anti-serovar 3 sera, absorbed rabbit anti-serovar 3 sera, and MAb 10C6.6. It is noteworthy that in the peptide scans, the intensity of the signal showed a trend to increase for all antibodies analyzed (Fig. 1) as the number of repeats (number of epitopes) increased; the exception, as expected, was the flat signal for the absorbed rabbit sera, which were depleted of serovar 3 antibodies. The rabbit antiserum profiles did not show any well-resolved individual peaks as did the patient serum profile. However, the rabbit anti-serovar 3 peaks for the shorter peptides (1 to 19) correlate well with the MAb 10C6.6 peaks. As the peptides increase in length, new epitopes are formed and the signal becomes more complex. For example, peptide 21 provides a new dominant epitope (EQPAGKE), which reappears in peptides 26 and 27 and then again in peptides 31 through 33. After this point, the specificity of the signals is less clear, most likely because additional overlapping epitopes are recognized by the polyclonal sera.

If the peak patient response had been directed to the serovar-specific epitope KEQPA, it would have indicated that the





Serotype 14

FIG. 2. Immunoreactive sites of the repeat region in the MB antigen. One repeat unit is GKEQPA for serovar 3 and GKEQQPA for serovar 14. MAb 10C6.6 is serovar 3 specific, MAb 5B1.1 cross-reacts between serovars 3 and 14, and MAb 3B1.5 reacts strongly with serovar 3 and shows weak nonspecific cross-reactions with other serovars. The patient serum response is to an epitope common to serovars 3 and 14. All identified epitopes are either overlapping or juxtaposed. The dashed arrows indicate the disruption of two epitopes in the serovar 14 sequence compared with the serovar 3 sequence.

patient had been exposed to U. urealyticum serovar 3. In fact, this epitope is represented by peptide 8 and shows marginal reactivity with the patient antibody, whereas the major patient response is to the epitope PAGK, which may be either specific or cross-reactive. Immunoblot analysis of this patient's serum had previously shown strong reactivity not only with U. urealyticum serovar 3 but also with serovar 14 and to a lesser extent serovar 1. Whether this particular patient's peak response was serovar specific cannot be determined until corresponding regions of the other serovars have been sequenced. We have now sequenced the mba gene of serovar 14. Previously described PCR primers UMS-125 and UMA1213 were used to amplify the serovar 14 mba gene, and then the product was cloned and sequenced by our standard procedures (17). The serovar 14 mba gene sequence is identical to that for serovar 3 with the exception of an additional glutamine residue (Q) in each repeat unit (Fig. 2). It can now be seen (Fig. 2) that the epitope recognized by patient serum, PAGK, is common to serovars 3 and 14. It can also be seen that MAbs 10C6.6 and 3B1.5 should not recognize serovar 14 and that one of the major rabbit epitopes discussed above, EQPAGKE, appears not to be found in serovar 14.

Sequence analysis was performed with the Genetics Computer Group program (University of Wisconsin-Madison) on a VAX-VMS computer at the University of Alabama at Birmingham. Interestingly, the antigenic index (AI) of the MB antigen amino acid sequence (Fig. 3) calculated as described by Jameson and Wolf (6) (Table 2) predicts that sequences containing the residues PAG should be the most antigenic. Both the patient (PAGK) and rabbit (EQPAGKE) major epi-

1	MKLLKNKKFW	AMTLGVTLVG	AGIVAIAASC	SNSTVESELS	NQFARSTDGK
51	SFYAVYBIEN	FEDLÖNDDER	SLSNIEFNAA	LTSAENKTES	TLEKGHLVGE
101	KIYVKLPREP	RPNEOLTIIS	KSGLIKTSGL	LISDNLNYQT	BKVNFETTQP
151	GKEQPAGKEQ	<u>PAG</u> KEQPAGK	e <u>opag</u> keopa	greq <u>pag</u> keq	PAGKE <u>QPAG</u> K
201	BQPAGKEQ <u>PA</u>	GREOPAGREO	<u>PAG</u> KEQPAGK	eq <u>pag</u> keqpa	GRE <u>QPAG</u> REQ
251	PAGKE <u>OPAG</u> K	EQPAGKEQ <u>PA</u>	<u>G</u> KEQPAGKEQ	<u>PAG</u> KBQPAGK	B <u>qpag</u> keqpa
301	greq <u>pag</u> req	PAGKE <u>OPAG</u> K	EQPAGREQ <u>PA</u>	<u>G</u> KEQPAGKEQ	<u>PAG</u> KEQPAGK
351	EQ <u>PAG</u> KEQPA	gre <u>opag</u> keq	PAGKEQ <u>PAG</u> K	EQPACKEOPA	GREQPACKEQ
401	<u>pag</u> rettgr*				

FIG. 3. Complete amino acid sequence of the U. urealyticum serovar 3 mba gene product. Calculation of the AI for this sequence was based on the method of Jameson and Wolf (6). The repetitive region begins at residue 151 and extends to residue 405. A symmetric distribution of antigenic sites is predicted for the repeat region. The highest AI is indicated by the underline at alternating PAG residues, beginning at residue 161.

topes contain these residues. It is also predicted (Fig. 3) that only every other PAG will have this property because alternating PAG residues are involved in loops (turns likely to be more antigenic, residues 161 to 163) or the less antigenic helices (residues 153 to 160). Residues 152 and 164 represent random coil. If the specific epitopes with the sequence EQPAGKE (loop flanked by alpha helices), defined by the rabbit antisera, are separately expressed along the repeat region of this molecule, then each individual copy of this epitope would be separated from the next by the less antigenic sequence QPAGK (only alpha helices).

The sequence of the native carboxy terminus deduced from the mba gene sequence of serovar 3 (17), including the terminal 2 1/2 repeat units, is GKEQPAGKEQPAGKETTGK. Careful examination of Fig. 1 and Table 1 reveals that the peak patient response was to the epitope defined by PAGK only if it occurred at the C terminus of the peptide. If PAGK was followed by E, as always occurs in the native protein, it was not recognized, implying that this particular subset of the patient's polyclonal antibodies would never recognize the native U. urealyticum serovar 3 molecule. The only exception to this was the

TABLE 2. Parameters used to calculate the AI

Residue position ^a	aa ^b	Hydro- philicity ^c	Surface probability ^d	Chain flexibility ^e	Secondary structure ^f	AI ^g
151	G	2.443	3.644	1.111	Т	1.300
152^{h}	Κ	2.571	3.253	1.111		0.900
153	E	1.814	2.126	1.106	h	0.900
154	Q	1.643	2.126	1.103	h	0.900
155	Р	2.143	2.126	1.089	h	0.900
156	Α	2.086	2.126	1.078	h	0.900
157	G	2.086	2.126	1.079	h	0.900
158	Κ	1.814	2.126	1.085	h	0.900
159	E	1.329	2.126	1.093	h	0.900
160	Q	1.643	2.126	1.097	h	0.900
161	Р	2.143	2.126	1.089	t	1.100
162	Α	2.086	2.126	1.078	t	1.100
163	G	2.086	2.126	1.079	t	1.100
164	Κ	1.814	2.126	1.085		0.900
165	E	1.329	2.126	1.093	h	0.900
166	Q	1.643	2.126	1.097	h	0.900

^a Residue position in primary sequence.

^b aa, amino acid.

^c Determined by the method of Kyte and Doolittle (9).

^d Determined by the method of Emini et al. (5). ^e Determined by the method of Karplus and Schulz (8).

^f Predicted by the method of Chou and Fasman (3). T, beta turn; h or t, weak secondary structure.

g Determined by the method of Jameson and Wolf (6).

^h The pattern between this residue and residue 163 (inclusive) is repeated to residue 403.

lack of reactivity with the C-terminal PAGK of peptide 15. This observation may be explained by a previous report (4, 10) demonstrating that the presence of a glutamic or aspartic acid residue at the amino terminus of a short peptide (two to seven residues) decreases antibody binding because of the ionic nature of these amino acids. A potential scenario for this patient is that the epitope PAGK may have resulted from partial processing of the U. urealyticum serovar 3 MB antigen and that this altered antigen actually elicited the antibody response. This processing could be a result of the normal defenses of the infected host or a consequence of organism-directed self processing of a premature protein, as, for example, in certain viruses (7). Alternatively, this population of antibodies may have been elicited by infection with another serovar in which the sequence PAGK is expressed at the carboxy terminus of the native protein.

The above discussions reveal the difficulty one encounters when trying to detect a serovar-specific polyclonal antibody response even if purified antigen containing serovar-specific epitopes and its amino acid sequence are available. These data also demonstrate the usefulness of one of our goals: once sequence data have been obtained for the variable region of all serovars, we should be able to effectively characterize a patient antibody response to the *U. urealyticum* MB antigens. Sequence comparisons of the different serovars will allow the selection of nonredundant peptides among the serovars to be used for serovar-specific antibody detection. This approach will allow us to discern differences in populations of patients with respect to responses to specific serovars as well as to specific MB epitopes within a serovar and to determine if there is any correlation with invasive versus noninvasive infections.

The serovar 14 sequence obtained in this study was assigned GenBank accession number U50462.

This work was supported by PHS grant AI 28279 from the National Institutes of Allergy and Infectious Diseases. MAbs were produced by the Hybridoma Core Facility of the Multipurpose Arthritis Center at the University of Alabama at Birmingham, which is supported by PHS grant 5P 60AR20614.

REFERENCES

 Cassell, G. H., K. B. Waites, D. T. Crouse, P. T. Rudd, K. C. Kanupp, S. Stagno, and G. R. Cutter. 1988. Association of *Ureaplasma urealyticum* infection of the lower respiratory tract with chronic lung disease and death in very low birth weight infants. Lancet ii:240–245.

- Cassell, G. H., K. B. Waites, H. L. Watson, D. T. Crouse, and R. Harasawa. 1993. Ureaplasma urealyticum intrauterine infection: role in prematurity and disease in newborns. Clin. Microbiol. Rev. 6:69–87.
- Chou, P. Y., and G. D. Fasman. 1978. Prediction of the secondary structure of proteins from their amino acid sequence. Adv. Enzymol. Relat. Areas Mol. Biol. 47:45–148.
- Day, E. D. 1990. The immunochemistry of some non-viral multiepitopic antigens, p. 521–602. *In* E. D. Day (ed.), Advanced immunochemistry, 2nd ed. Wiley-Liss, Inc., New York.
- Emini, E. A., J. V. Hughes, D. S. Perlow, and J. Boger. 1985. Induction of hepatitis A virus-neutralizing antibody by a virus-specific synthetic peptide. J. Virol. 55:836–839.
- Jameson, B. A., and H. Wolf. 1988. Predicting antigenicity from protein primary structure: a new algorithm for the prediction of antigenic sites. Comput. Appl. Biosci. 4:181–186.
- Kaplan, A. H., M. Manchester, and R. Swanstrom. 1994. The activity of the protease of human immunodeficiency virus type 1 is initiated at the membrane of infected cells before the release of viral proteins and is required for release to occur with maximum efficiency. J. Virol. 68:6782–6786.
- Karplus, P. A., and G. E. Schulz. 1985. Prediction of chain flexibility in proteins. Naturwissenschaften 72:212–213.
- Kyte, J., and R. F. Doolittle. 1983. A simple method for displaying the hydropathic character of a protein. J. Mol. Biol. 157:105–132.
- Shi, P. T., J. P. Riehm, P. E. E. Todd, and S. J. Leach. 1984. The antigenicity of myoglobin-related peptides synthesised on polyacrylamide and polystyrene resin supports. Mol. Immunol. 21:489–496.
- Teng, L.-J., X. Zheng, J. I. Glass, H. L. Watson, J. Tsai, and G. H. Cassell. 1994. Ureaplasma urealyticum biovar specificity and diversity are encoded in multiple-banded antigen gene. J. Clin. Microbiol. 32:1464–1469.
- Tribbick, G., B. Triantafyllou, R. Lauricella, S. J. Rodda, T. J. Mason, and H. M. Geysen. 1991. Systematic fractionation of serum antibodies using multiple antigen homologous peptides as affinity ligands. J. Immunol. Methods 139:155–166.
- Waites, K. B., D. T. Crouse, and G. H. Cassell. 1990. Ureaplasma and mycoplasma CNS infections in newborn babies. Lancet 335:658–659.
- Waites, K. B., L. B. Duffy, D. T. Crouse, M. E. Dworsky, M. J. Strange, K. G. Nelson, and G. H. Cassell. 1990. Mycoplasmal infections of cerebrospinal fluid in newborn infants from a community hospital population. Pediatr. Infect. Dis. J. 9:241–245.
- Watson, H. L., D. K. Blalock, and G. H. Cassell. 1990. Variable antigens of Ureaplasma urealyticum containing both serovar-specific and serovar-crossreactive epitopes. Infect. Immun. 58:3679–3688.
- Wise, K. S., D. Yogev, and R. Rosengarten. 1992. Antigenic variation, p. 473–489. *In J. Maniloff, R. N. McElhaney, L. R. Finch, and J. B. Baseman* (ed.), Mycoplasmas: molecular biology and pathogenesis. American Society for Microbiology, Washington, D.C.
- Zheng, X., L.-J. Teng, H. L. Watson, J. I. Glass, A. Blanchard, and G. H. Cassell. 1995. Small repeating units within the *Ureaplasma urealyticum* MB antigen gene encode serovar specificity and are associated with antigen size variation. Infect. Immun. 63:891–898.
- Zheng, X., H. L. Watson, K. B. Waites, and G. H. Cassell. 1992. Serotype diversity and antigen variation among invasive isolates of *Ureaplasma urealyticum* from neonates. Infect. Immun. 60:3472–3474.